Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share

Tiger Newspress2021-10-29

Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share.Entrada, which is working to develop therapeutics for rare neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy type 1, said it believes the proceeds, coupled with its existing resources, will be sufficient to fund its operating expenses and capital-spending needs into the second quarter of 2024.

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

Bull1973
2021-10-30
Bull1973
Ok
- ocean_wave:
  [强]
chamomile
2021-10-30
chamomile
Cool
- Bull1973:
  Ok
Ong2021
2021-10-30
Ong2021
[Smile]
- Ong2021:
  [What]
Jeezz
2021-10-30
Jeezz
wow
- Waeisiong:
  ok
Gackky
2021-10-30
Gackky
i also jump over 25% of losses so far[Spurting]
- Gackky:
  played the game. thanks for ur guidance😍
- Venus_M:
  today last day
- Venus_M:
  come over to my page. new game. Last day to play 31st October.
k1wong
2021-10-30
k1wong
Ok

发表看法

122

340

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1170077439?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-10-29 23:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170077439","market":"us","top_or_hot":-1,"title":"Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share","media":"Tiger Newspress","content":"<p>Entrada&nbsp;jumped&nbsp;over&nbsp;30%&nbsp;in&nbsp;morning&nbsp;trading,above&nbsp;its&nbsp;IPO&nbsp;price&nbsp;at&nbsp;20&nbsp;dollars&nbsp;per&nbsp;share.<img src=\"https://static.tigerbbs.com/d7b5af9ada5c6d243935e675a495b080\" tg-width=\"769\" tg-height=\"570\" width=\"100%\" height=\"auto\">Entrada, which is working to develop therapeutics for rare neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy type 1, said it believes the proceeds, coupled with its existing resources, will be sufficient to fund its operating expenses and capital-spending needs into the second quarter of 2024.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEntrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share\n</h2>\n\n<h4 class=\"meta\">\n\n2021-10-29 23:29 北京时间&nbsp;&nbsp;&nbsp;<strong>Tiger Newspress</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share.Entrada, which is working to develop therapeutics for rare neuromuscular diseases such as Duchenne muscular ...</p>\n\n<a href=\"None\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TRDA","symbol_name":"Entrada Therapeutics, Inc.","start_time":0,"source_url":null,"article_id":"1170077439","we_media_id":"1079075236","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170077439","pubTimestamp":1635521388,"sourceInfo":null,"weMediaInfo":{"media_name":"Tiger Newspress","introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share.Entrada, which is working to develop therapeutics for rare neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy type 1, said it believes the proceeds, coupled with its existing resources, will be sufficient to fund its operating expenses and capital-spending needs into the second quarter of 2024.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TRDA":"Entrada Therapeutics, Inc."},"translate_title":"Entrada在早盘交易中上涨超过30%，高于每股20美元的IPO价格","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TRDA":0.9},"content_text":"Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share.Entrada, which is working to develop therapeutics for rare neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy type 1, said it believes the proceeds, coupled with its existing resources, will be sufficient to fund its operating expenses and capital-spending needs into the second quarter of 2024.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":840304447,"gmtCreate":1635583719116,"gmtModify":1635583719283,"author":{"id":"3584680402793671","authorId":"3584680402793671","name":"Bull1973","avatar":"https://static.tigerbbs.com/866d29bf88ff7363d121a5ccc6028aae","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/840304447","repostId":1170077439,"repostType":4,"repost":{"id":"1170077439","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635521388,"share":"https://www.laohu8.com/m/news/1170077439?lang=&edition=full","pubTime":"2021-10-29 23:29","market":"us","language":"en","title":"Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share","url":"https://stock-news.laohu8.com/highlight/detail?id=1170077439","media":"Tiger Newspress","summary":"Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share.Entrada, which is working to develop therapeutics for rare neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy type 1, said it believes the proceeds, coupled with its existing resources, will be sufficient to fund its operating expenses and capital-spending needs into the second quarter of 2024.","content":"<p>Entrada&nbsp;jumped&nbsp;over&nbsp;30%&nbsp;in&nbsp;morning&nbsp;trading,above&nbsp;its&nbsp;IPO&nbsp;price&nbsp;at&nbsp;20&nbsp;dollars&nbsp;per&nbsp;share.<img src=\"https://static.tigerbbs.com/d7b5af9ada5c6d243935e675a495b080\" tg-width=\"769\" tg-height=\"570\" width=\"100%\" height=\"auto\">Entrada, which is working to develop therapeutics for rare neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy type 1, said it believes the proceeds, coupled with its existing resources, will be sufficient to fund its operating expenses and capital-spending needs into the second quarter of 2024.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEntrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-29 23:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Entrada&nbsp;jumped&nbsp;over&nbsp;30%&nbsp;in&nbsp;morning&nbsp;trading,above&nbsp;its&nbsp;IPO&nbsp;price&nbsp;at&nbsp;20&nbsp;dollars&nbsp;per&nbsp;share.<img src=\"https://static.tigerbbs.com/d7b5af9ada5c6d243935e675a495b080\" tg-width=\"769\" tg-height=\"570\" width=\"100%\" height=\"auto\">Entrada, which is working to develop therapeutics for rare neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy type 1, said it believes the proceeds, coupled with its existing resources, will be sufficient to fund its operating expenses and capital-spending needs into the second quarter of 2024.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRDA":"Entrada Therapeutics, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170077439","content_text":"Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share.Entrada, which is working to develop therapeutics for rare neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy type 1, said it believes the proceeds, coupled with its existing resources, will be sufficient to fund its operating expenses and capital-spending needs into the second quarter of 2024.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6393459,"gmtCreate":1635648516588,"gmtModify":1635648516689,"authorId":3578971018458145,"author":{"id":3578971018458145,"authorId":3578971018458145,"name":"ocean_wave","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":840304447,"type":1,"supId":0,"prevId":0,"content":"[强]","text":"[强]","html":"[强]"}],"langContent":"CN"},{"id":840937747,"gmtCreate":1635574025098,"gmtModify":1635574025098,"author":{"id":"4093267928826650","authorId":"4093267928826650","name":"chamomile","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":8,"crmLevelSwitch":0},"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/840937747","repostId":1170077439,"repostType":4,"repost":{"id":"1170077439","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635521388,"share":"https://www.laohu8.com/m/news/1170077439?lang=&edition=full","pubTime":"2021-10-29 23:29","market":"us","language":"en","title":"Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share","url":"https://stock-news.laohu8.com/highlight/detail?id=1170077439","media":"Tiger Newspress","summary":"Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share.Entrada, which is working to develop therapeutics for rare neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy type 1, said it believes the proceeds, coupled with its existing resources, will be sufficient to fund its operating expenses and capital-spending needs into the second quarter of 2024.","content":"<p>Entrada&nbsp;jumped&nbsp;over&nbsp;30%&nbsp;in&nbsp;morning&nbsp;trading,above&nbsp;its&nbsp;IPO&nbsp;price&nbsp;at&nbsp;20&nbsp;dollars&nbsp;per&nbsp;share.<img src=\"https://static.tigerbbs.com/d7b5af9ada5c6d243935e675a495b080\" tg-width=\"769\" tg-height=\"570\" width=\"100%\" height=\"auto\">Entrada, which is working to develop therapeutics for rare neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy type 1, said it believes the proceeds, coupled with its existing resources, will be sufficient to fund its operating expenses and capital-spending needs into the second quarter of 2024.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEntrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-29 23:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Entrada&nbsp;jumped&nbsp;over&nbsp;30%&nbsp;in&nbsp;morning&nbsp;trading,above&nbsp;its&nbsp;IPO&nbsp;price&nbsp;at&nbsp;20&nbsp;dollars&nbsp;per&nbsp;share.<img src=\"https://static.tigerbbs.com/d7b5af9ada5c6d243935e675a495b080\" tg-width=\"769\" tg-height=\"570\" width=\"100%\" height=\"auto\">Entrada, which is working to develop therapeutics for rare neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy type 1, said it believes the proceeds, coupled with its existing resources, will be sufficient to fund its operating expenses and capital-spending needs into the second quarter of 2024.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRDA":"Entrada Therapeutics, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170077439","content_text":"Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share.Entrada, which is working to develop therapeutics for rare neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy type 1, said it believes the proceeds, coupled with its existing resources, will be sufficient to fund its operating expenses and capital-spending needs into the second quarter of 2024.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6386056,"gmtCreate":1635583730334,"gmtModify":1635583730445,"authorId":3584680402793671,"author":{"id":3584680402793671,"authorId":3584680402793671,"name":"Bull1973","avatar":"https://static.tigerbbs.com/866d29bf88ff7363d121a5ccc6028aae","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":840937747,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":857758394,"gmtCreate":1635562933431,"gmtModify":1635562933504,"author":{"id":"4087873768935830","authorId":"4087873768935830","name":"Ong2021","avatar":"https://static.tigerbbs.com/eec6b0f9969a9aab1913945a2c49ea24","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/857758394","repostId":1170077439,"repostType":4,"repost":{"id":"1170077439","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635521388,"share":"https://www.laohu8.com/m/news/1170077439?lang=&edition=full","pubTime":"2021-10-29 23:29","market":"us","language":"en","title":"Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share","url":"https://stock-news.laohu8.com/highlight/detail?id=1170077439","media":"Tiger Newspress","summary":"Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share.Entrada, which is working to develop therapeutics for rare neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy type 1, said it believes the proceeds, coupled with its existing resources, will be sufficient to fund its operating expenses and capital-spending needs into the second quarter of 2024.","content":"<p>Entrada&nbsp;jumped&nbsp;over&nbsp;30%&nbsp;in&nbsp;morning&nbsp;trading,above&nbsp;its&nbsp;IPO&nbsp;price&nbsp;at&nbsp;20&nbsp;dollars&nbsp;per&nbsp;share.<img src=\"https://static.tigerbbs.com/d7b5af9ada5c6d243935e675a495b080\" tg-width=\"769\" tg-height=\"570\" width=\"100%\" height=\"auto\">Entrada, which is working to develop therapeutics for rare neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy type 1, said it believes the proceeds, coupled with its existing resources, will be sufficient to fund its operating expenses and capital-spending needs into the second quarter of 2024.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEntrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-29 23:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Entrada&nbsp;jumped&nbsp;over&nbsp;30%&nbsp;in&nbsp;morning&nbsp;trading,above&nbsp;its&nbsp;IPO&nbsp;price&nbsp;at&nbsp;20&nbsp;dollars&nbsp;per&nbsp;share.<img src=\"https://static.tigerbbs.com/d7b5af9ada5c6d243935e675a495b080\" tg-width=\"769\" tg-height=\"570\" width=\"100%\" height=\"auto\">Entrada, which is working to develop therapeutics for rare neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy type 1, said it believes the proceeds, coupled with its existing resources, will be sufficient to fund its operating expenses and capital-spending needs into the second quarter of 2024.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRDA":"Entrada Therapeutics, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170077439","content_text":"Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share.Entrada, which is working to develop therapeutics for rare neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy type 1, said it believes the proceeds, coupled with its existing resources, will be sufficient to fund its operating expenses and capital-spending needs into the second quarter of 2024.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6382255,"gmtCreate":1635562943219,"gmtModify":1635562943250,"authorId":4087873768935830,"author":{"id":4087873768935830,"authorId":4087873768935830,"name":"Ong2021","avatar":"https://static.tigerbbs.com/eec6b0f9969a9aab1913945a2c49ea24","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":857758394,"type":1,"supId":0,"prevId":0,"content":"[What]","text":"[What]","html":"[What]"}],"langContent":"CN"},{"id":857486333,"gmtCreate":1635555399279,"gmtModify":1635555399379,"author":{"id":"4087967048754970","authorId":"4087967048754970","name":"Jeezz","avatar":"https://static.tigerbbs.com/a70af8809a95756364cc82fcfde2f404","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/857486333","repostId":1170077439,"repostType":4,"repost":{"id":"1170077439","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635521388,"share":"https://www.laohu8.com/m/news/1170077439?lang=&edition=full","pubTime":"2021-10-29 23:29","market":"us","language":"en","title":"Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share","url":"https://stock-news.laohu8.com/highlight/detail?id=1170077439","media":"Tiger Newspress","summary":"Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share.Entrada, which is working to develop therapeutics for rare neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy type 1, said it believes the proceeds, coupled with its existing resources, will be sufficient to fund its operating expenses and capital-spending needs into the second quarter of 2024.","content":"<p>Entrada&nbsp;jumped&nbsp;over&nbsp;30%&nbsp;in&nbsp;morning&nbsp;trading,above&nbsp;its&nbsp;IPO&nbsp;price&nbsp;at&nbsp;20&nbsp;dollars&nbsp;per&nbsp;share.<img src=\"https://static.tigerbbs.com/d7b5af9ada5c6d243935e675a495b080\" tg-width=\"769\" tg-height=\"570\" width=\"100%\" height=\"auto\">Entrada, which is working to develop therapeutics for rare neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy type 1, said it believes the proceeds, coupled with its existing resources, will be sufficient to fund its operating expenses and capital-spending needs into the second quarter of 2024.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEntrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-29 23:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Entrada&nbsp;jumped&nbsp;over&nbsp;30%&nbsp;in&nbsp;morning&nbsp;trading,above&nbsp;its&nbsp;IPO&nbsp;price&nbsp;at&nbsp;20&nbsp;dollars&nbsp;per&nbsp;share.<img src=\"https://static.tigerbbs.com/d7b5af9ada5c6d243935e675a495b080\" tg-width=\"769\" tg-height=\"570\" width=\"100%\" height=\"auto\">Entrada, which is working to develop therapeutics for rare neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy type 1, said it believes the proceeds, coupled with its existing resources, will be sufficient to fund its operating expenses and capital-spending needs into the second quarter of 2024.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRDA":"Entrada Therapeutics, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170077439","content_text":"Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share.Entrada, which is working to develop therapeutics for rare neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy type 1, said it believes the proceeds, coupled with its existing resources, will be sufficient to fund its operating expenses and capital-spending needs into the second quarter of 2024.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6379953,"gmtCreate":1635555633849,"gmtModify":1635555633952,"authorId":3581590310925129,"author":{"id":3581590310925129,"authorId":3581590310925129,"name":"Waeisiong","avatar":"https://static.tigerbbs.com/058e1e1ecb51258cff6ed86fb0c17292","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":857486333,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"}],"langContent":"CN"},{"id":857541575,"gmtCreate":1635551999093,"gmtModify":1635551999676,"author":{"id":"3574326723774097","authorId":"3574326723774097","name":"Gackky","avatar":"https://static.tigerbbs.com/5898b44bf5a31bf2b9d4e37227ed8177","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"i also jump over 25% of losses so far[Spurting]&nbsp;","listText":"i also jump over 25% of losses so far[Spurting]&nbsp;","text":"i also jump over 25% of losses so far[Spurting]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/857541575","repostId":1170077439,"repostType":4,"repost":{"id":"1170077439","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635521388,"share":"https://www.laohu8.com/m/news/1170077439?lang=&edition=full","pubTime":"2021-10-29 23:29","market":"us","language":"en","title":"Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share","url":"https://stock-news.laohu8.com/highlight/detail?id=1170077439","media":"Tiger Newspress","summary":"Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share.Entrada, which is working to develop therapeutics for rare neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy type 1, said it believes the proceeds, coupled with its existing resources, will be sufficient to fund its operating expenses and capital-spending needs into the second quarter of 2024.","content":"<p>Entrada&nbsp;jumped&nbsp;over&nbsp;30%&nbsp;in&nbsp;morning&nbsp;trading,above&nbsp;its&nbsp;IPO&nbsp;price&nbsp;at&nbsp;20&nbsp;dollars&nbsp;per&nbsp;share.<img src=\"https://static.tigerbbs.com/d7b5af9ada5c6d243935e675a495b080\" tg-width=\"769\" tg-height=\"570\" width=\"100%\" height=\"auto\">Entrada, which is working to develop therapeutics for rare neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy type 1, said it believes the proceeds, coupled with its existing resources, will be sufficient to fund its operating expenses and capital-spending needs into the second quarter of 2024.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEntrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-29 23:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Entrada&nbsp;jumped&nbsp;over&nbsp;30%&nbsp;in&nbsp;morning&nbsp;trading,above&nbsp;its&nbsp;IPO&nbsp;price&nbsp;at&nbsp;20&nbsp;dollars&nbsp;per&nbsp;share.<img src=\"https://static.tigerbbs.com/d7b5af9ada5c6d243935e675a495b080\" tg-width=\"769\" tg-height=\"570\" width=\"100%\" height=\"auto\">Entrada, which is working to develop therapeutics for rare neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy type 1, said it believes the proceeds, coupled with its existing resources, will be sufficient to fund its operating expenses and capital-spending needs into the second quarter of 2024.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRDA":"Entrada Therapeutics, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170077439","content_text":"Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share.Entrada, which is working to develop therapeutics for rare neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy type 1, said it believes the proceeds, coupled with its existing resources, will be sufficient to fund its operating expenses and capital-spending needs into the second quarter of 2024.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6392085,"gmtCreate":1635643867452,"gmtModify":1635643867486,"authorId":3574326723774097,"author":{"id":3574326723774097,"authorId":3574326723774097,"name":"Gackky","avatar":"https://static.tigerbbs.com/5898b44bf5a31bf2b9d4e37227ed8177","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":857541575,"type":1,"supId":0,"prevId":0,"content":"played the game. thanks for ur guidance😍","text":"played the game. thanks for ur guidance😍","html":"played the game. thanks for ur guidance😍"},{"id":6386422,"gmtCreate":1635588037157,"gmtModify":1635588037157,"authorId":3566385558470298,"author":{"id":3566385558470298,"authorId":3566385558470298,"name":"Venus_M","avatar":"https://static.tigerbbs.com/525433622d774840840ddaacaf2281d2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":857541575,"type":1,"supId":6386419,"prevId":0,"content":"today last <u>day</u>","text":"today last <u>day</u>","html":"today last <u>day</u>"},{"id":6386419,"gmtCreate":1635588006179,"gmtModify":1635588006179,"authorId":3566385558470298,"author":{"id":3566385558470298,"authorId":3566385558470298,"name":"Venus_M","avatar":"https://static.tigerbbs.com/525433622d774840840ddaacaf2281d2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":857541575,"type":1,"supId":0,"prevId":0,"content":"come over to my page. new game. Last day to play 31st October.","text":"come over to my page. new game. Last day to play 31st October.","html":"come over to my page. new game. Last day to play 31st October."}],"langContent":"CN"},{"id":857540927,"gmtCreate":1635551767757,"gmtModify":1635551767846,"author":{"id":"3574996050082067","authorId":"3574996050082067","name":"k1wong","avatar":"https://static.tigerbbs.com/f9f3b0884767b721ac5720e7a17adeba","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/857540927","repostId":1170077439,"repostType":4,"repost":{"id":"1170077439","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635521388,"share":"https://www.laohu8.com/m/news/1170077439?lang=&edition=full","pubTime":"2021-10-29 23:29","market":"us","language":"en","title":"Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share","url":"https://stock-news.laohu8.com/highlight/detail?id=1170077439","media":"Tiger Newspress","summary":"Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share.Entrada, which is working to develop therapeutics for rare neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy type 1, said it believes the proceeds, coupled with its existing resources, will be sufficient to fund its operating expenses and capital-spending needs into the second quarter of 2024.","content":"<p>Entrada&nbsp;jumped&nbsp;over&nbsp;30%&nbsp;in&nbsp;morning&nbsp;trading,above&nbsp;its&nbsp;IPO&nbsp;price&nbsp;at&nbsp;20&nbsp;dollars&nbsp;per&nbsp;share.<img src=\"https://static.tigerbbs.com/d7b5af9ada5c6d243935e675a495b080\" tg-width=\"769\" tg-height=\"570\" width=\"100%\" height=\"auto\">Entrada, which is working to develop therapeutics for rare neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy type 1, said it believes the proceeds, coupled with its existing resources, will be sufficient to fund its operating expenses and capital-spending needs into the second quarter of 2024.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEntrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-29 23:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Entrada&nbsp;jumped&nbsp;over&nbsp;30%&nbsp;in&nbsp;morning&nbsp;trading,above&nbsp;its&nbsp;IPO&nbsp;price&nbsp;at&nbsp;20&nbsp;dollars&nbsp;per&nbsp;share.<img src=\"https://static.tigerbbs.com/d7b5af9ada5c6d243935e675a495b080\" tg-width=\"769\" tg-height=\"570\" width=\"100%\" height=\"auto\">Entrada, which is working to develop therapeutics for rare neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy type 1, said it believes the proceeds, coupled with its existing resources, will be sufficient to fund its operating expenses and capital-spending needs into the second quarter of 2024.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRDA":"Entrada Therapeutics, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170077439","content_text":"Entrada jumped over 30% in morning trading,above its IPO price at 20 dollars per share.Entrada, which is working to develop therapeutics for rare neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy type 1, said it believes the proceeds, coupled with its existing resources, will be sufficient to fund its operating expenses and capital-spending needs into the second quarter of 2024.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":340,"commentSize":122,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1170077439"}